Wissenschaft

Aktuelle retrospektive Studien

„Allogeneic transplantation for therapy-related myeloid neoplasms – Outcome analysis with regard to the primary malignancy and the therapy-related myeloid disorder“

„Multizentrische, retrospektive Analyse zum ereignisfreien Überleben von allogen stammzelltransplantierten Patienten mit rezidivierter chronischer myeloischer Leukämie“

„Validierung eines Prognosescores für die Post-transplant lymphoproliferative Erkrankung (PTLD) nach allogener Stammzelltransplantation“

„Retrospektive Analyse der DRST Registerdaten zum Überleben Heranwachsender und junger Erwachsenen (AYA) nach allogener Stammzelltransplantation in Deutschland“

„Untersuchung des Einflusses genetischer Polymorphismen für die intrazelluläre Signalweitergabe bei akuter Transplantat gegen Wirt Erkrankung“

„Retrospective analysis of allogeneic hematopoietic stem cell transplantation (HSCT) in the treatment of relapse of myeloid neoplasia after a first allogeneic HSCT“

„Outcome von Patienten mit IDH1/2-mutierter AML nach allogener Blutstammzelltransplantation“

„Evaluierung der Stammzelltransplantation als einzig potentiell kurative Therapielinie in der T-Zell Prolymphozytenleukämie“

„Salvage Therapy with Inotuzumab ozogamicin before or after allogeneic stem cell transplantation, Real World Outcomes“

„Efficacy of an allogeneic transplant and understanding the complex competing risks and multistate structure of aftercare – Analysis of German transplant registry data -“

„Vergleich Haplo-Tx Protokolle mit 10/10 identer unverwandter Blutstammzelltransplantation (Matched Pair Registerdatenanalyse)“

„Real Word Data Brexucabtagene autoleucel Germany“

„Artificial intelligence and causal inference to identify patients with early relapse or long-term survival after autologous stem cell transplantation for newly diagnosed multiple myeloma“

„Machbarkeitsabfrage zur Vorbereitung einer Benchmarkanalyse zur Evaluation von zentrumsbezogenen Einflussfaktoren auf das Ergebnis einer allogenen Stammzelltransplantation bei Patienten nach allogener Ersttransplantation vom Fremd- oder Familienspender bei AML“

„Einordnung des „CMML transplant scores“ – ROC-Kurve zur Analyse der Diskriminierung des Risikoscores“

„Vergleich Haplo-Tx Protokolle mit 9/10 identer unverwandter Blutstammzelltransplantation“

„Impact of maintenance therapy after allogeneic SCT for FLT3-ITD positive AML. Real world Data from Germam Registry for Stem Cell Transplantation“

„Upfront HCT versus remission induction in patients with MDS and hypoproliferative AML“

„Real World Data CAR-T cell therapy LBCL: Long-term FU + Liso-cel“

„Real World Analyse zu CAR-T Zelltherapie bei Multiplem Myelom in Deutschland“

„Retrospektive Analyse zur Evaluation von NK Zell Rezeptor – Ligand Kombinationen für die Auswahl unverwandter Stammzellspender“

„Klinischer Outcome nach Transfusion von Spenderlymphozyten (DLI) bei Patienten mit Hochrisiko akuter myeloischen Leukämie (AML) und myelodysplastischen Syndrom (MDS) in kompletter hematologischen Remission (CHR) nach allogener Stammzelltransplantation (AlloSCT) – Einfluss von genetischen Subtypen, Transplantations- und DLI-assozierten Parameter.“

„Der Einfluss von HLA-Differenzen mit Fokus auf HLA-DQB1 Differenzen auf den Erfolg der unverwandten Blutstammzelltransplantation. Auswertung der DRST Daten von Transplantationen aus den Jahren 2010-2021 zusammen mit HLA-Daten der Sucheinheit Ulm“

„Reduzierte posttransplant Cyclophosphamid-Dosis (ptCy) zur Prophylaxe der Graft-versus-Host Disease (GvHD) nach allogener Stammzelltransplantation (alloSZT)von Familienspendern (haplo-identical oder matched) oder unverwandten Spendern (mismatched oder matched)“

„Auswertung der DP-TCE Studie zum Einfluss von HLA-DPB1 Spender-Empfänger Differenzen auf das Outcome der 10/10 Fremdspendertransplantation für maligne hämatologische Erkrankungen“

Publikationen

2024

Hope for Motherhood: Pregnancy After Allogeneic Hematopoietic Cell Transplantation - a National Multicenter Study

Sockel K, Neu A, Goeckenjan M, et al. / Blood / 2024; blood.2024024342. doi: /10.1182/blood.2024024342

Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation

Gagelmann N, Schuh C, Zeiser, et al. 2024.Transplant Cell Ther, 2024 Aug 3, in press. doi: 10.1016/j.jtct.2024.07.026.

Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation

Gagelmann N, Schuh C, Flossdorf S, et al. American Journal of Hematology 2024 May 14. Epub ahead of print. doi: 10.1002/ajh.27363

Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin ATLG) in unrelated donor transplantation (ATOS study)

Finke J, Schmoor C, Ayuk F, et al. Bone Marrow Transplant 2024 Mar 16. Epub ahead of print. doi: 10.1038/s41409-024-02264-9. Erratum in: Bone Marrow Transplant. 2024 Apr 23

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Lübke J, Christen D, Schwaab J, et al. Leukemia 2024 Mar 6. doi 10.1038/s41375-024-02186-x.

Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study

Weller JF, Lengerke C, Finke J, et al. Haematologica 2024 Feb;109(2):431-443.

Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML.

Fein JA, Shouval R, Krieger E, et. al. Blood Adv 2024 8 (3): 581-590. doi 10.1182/bloodadvances.2023011622.

The impact of MICB mismatches in unrelated haematopoietic stem cell transplantation

Amann EM, Gowdavally S, Tsamadou C, et al. HLA. 2024;103(6):e15584. doi: 10.1111/tan.15584.

2023

Konkurrierende Risiken Modelle. In: Gertheiss, J., Schmid, M., Spindler, M. (eds) Moderne Verfahren der Angewandten Statistik 2023, pp 1-36

Schmeller S, Fürst D, Beyersmann J. Verlag Springer Spektrum, Berlin, Heidelberg. doi:10.1007/978-3-662-63496-7_4-1.

Outcomesof axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRSTregistry study

Schubert ML, Bethge WA, Ayuk FA, et al. Blood Adv 2023 Oct;7(20):6191-6195. doi: 10.1182/bloodadvances.2023011203.

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis

Derigs P, Bethge WA, Krämer I, et al. Transplant Cellular Ther 2023 Dec;29(12):750-756. doi: 10.1016/j.jtct.2023.09.008

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study

Ayuk F, Gagelmann N, von Tresckow B, et al. Blood Adv 2023 Sep;7(18):5316-5319. doi: 10.1182/bloodadvances.2023010336.

German Lymphoma Alliance (GLA); German Stem Cell Transplantation Registry (DRST). Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

Dreger P, Holtick U, Subklewe M, et al; Bone Marrow Transplant 2023 Feb;58(2):229-232. doi: 10.1038/s41409-022-01867-4

Outcomes after allogeneic haematopoietic stem cell transplantation in young adults in Germany

Frietsch JJ, Flossdorf S, Beck JF, Kröger N, Fleischhauer K, Dreger P, et al. Br J Haematol. 2023;201(2):308–318. doi: 10.1111/bjh.18610.

Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study

Gagelmann N, Wulf GG, Duell J, et al. Blood Adv. 2023 Feb 28;7(4):555-559. doi: 10.1182/bloodadvances.2022008042.

2022

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.

Bethge WA, Martus P, Schmitt M, et al. Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.

Higher risk for chronic graft-versus-host disease (GvHD) in HLA-G mismatched transplants following allogeneic hematopoietic stem cell transplantation: A retrospective study

C Neuchel, S Gowdavally, C Tsamadou, et al. HLA, 2022. doi:10.1111/tan.14733.

Donor genetic determinant of thymopoiesis rs2204985 impacts clinical outcome after single HLA mismatched hematopoietic stemm cell transplantation

C Tsamadou, S Gowdavally, U Platzbecker, et al. Bone Marrow Transplant., 2022. doi:10.1038/s41409-022-01751-1.

Zahl der Stammzelltransplantationen während der COVID-19-Pandemie

N Kröger, S Frank, H Neidlinger, et al. Dtsch Arztebl Int, 119(35-36):601–602, 2022. doi:10.3238/arztebl.m2022.0239.

2021

The human leukocyte antigen-dpb1 degree of compatibility is determined by its expression level and mismatch permissiveness: A german multicenter analysis

D Mytilineos, C Tsamadou, C Neuchel, et al. Frontiers in Immunology, 11, 2021. doi:10.3389/fimmu.2020.614976.

Hla-drb3/4/5 matching improves outcome of unrelated hematopoietic stem cell transplantation

C Tsamadou, D Engelhardt, U Platzbecker, et al. Frontiers in Immunology, 12, 2021. doi: 10.3389/fimmu.2021.771449.

2020

External validation of models for kir2ds1/kir3dl1-informed selection of hematopoietic cell donors fails

J Schetelig, H Baldauf F Heidenreich, et al. Blood, 135(16):1386–1395, 2020. doi:10.1182/blood.2019002887.

Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

L Jansen, M Merz, M Engelhardt, et al. Leukemia & Lymphoma, 61(10):2365–2374. 2020.doi:10.1080/10428194.2020.1768383

2018

Competing risks outcomes in hematopoietic stem cell transplantation from the perspective of time-dependent effects

D Fürst, S Frank, C Müller, et al. Haematologica 2018;103(9):1527-1534. doi: 10.3324/haematol.2017.183012.

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome

F Ayuk, DW Beelen, M Bornhäuser, et al. Biology of Blood and Marrow Transplantation, 24(12):2558–2567, Dezember 2018. doi:10.1016/j.bbmt.2018.06.026.

Allogeneic haematopoietic cell transplantation offers the chance of cure for patients with transformed follicular lymphoma

Heinzelmann, F., Bethge, W., Beelen, D.W. et al. J Cancer Res Clin Oncol 144, 1173–1183 (2018). doi: 10.1007/s00432-018-2633-5

2017

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors — A Retrospective Study

Neuchel C, Fürst D, Niederwieser D, et al. PLOS ONE, 12(1):e0169512, January 2017. doi:10.1371/journal.pone.0169512.

Increased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation

D Fürst, D Niederwieser, D Bunjes, et al. Haematologica, 102(4):796–803, April 2017. doi:10.3324/haematol.2016.151340.

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

C Tsamadou, D Fürst, V Vucinic, et al. Haematologica, 102(11):1947–1955, November 2017. doi:10.3324/haematol.2017.169805.

2016

Survival of elderly patients with multiple myeloma - Effect of upfront autologous stem cell transplantation

M Merz, L Jansen, FA Castro, et al. European Journal of Cancer, 62:1–8, 2016. Doi: 10.1016/j.ejca.2016.04.004

Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas

F Heinzelmann, W Bethge, DW Beelen, et al. Bone Marrow Transplantation, 51:654–662, 2016. doi:10.1038/bmt.2015.348.

Time-dependent effects of clinical predictors in unrelated hematopoietic stem cell transplantation

D Fürst, C Müller, DW Beelen, et al. Haematologica, 101(2):241–247, 2016. doi:10.3324/haematol.2015.130401.

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation

D Fürst, C Neuchel, D Niederwieser, et al. Blood, 128:3169–3176, 2016. doi:10.1182/ blood-2016-05-716357.

2015

Allogene Blutstammzelltransplantation: Aktuelle Informationen zum Standort Deutschland

H Ottinger and DW Beelen. Transfusionsmedizin, 5(03):126–130, 2015. doi: 10.1055/s-0034-1397916

Outcome after autologous stem cell transplantation for myeloma in patients beyond 60, 65 and 70 years of age: A retrospective Analysis from the German Registry for Stem Cell Transplantation (DRST)

M Merz, H Salwender, K Weisel, et al. Clinical Lymphoma, Myeloma and Leukemia, 15(Supplement 3):e149–e150, 2015. doi: 10.1016/j.clml.2015.07.354

2014

Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia

M Pfirrmann, S Saussele, A Hochhaus, et al. Journal of Cancer Research and Clinical Oncology, Published online, 2014. doi: 10.1007/s00432-014-1662-y.

2013

High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis

D Fürst, C Müller, V Vucinic, et al. Blood, 122(18):3220–3229, 2013. doi: 10.1182/blood-2013-02-482547

Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change

M Christopeit, O Kuss, J Finke, et al. Journal of Clinical Oncology, 31(26):3259–3271, 2013. Doi: 10.1200/JCO.2012.44.7961

2011

The EBMT activity survey 2009: trends over the past 5 years

H Baldomero, M Gratwohl, A Gratwohl, et al. Bone Marrow Transplantation, 46:485-501, 2011 doi: 10.1038/bmt.2011.11

Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial

M Stelljes, DW Beelen, J Braess, et al. Haematologica, 96(7):972-979, 2011. doi: 10.3324/haematol.2011.041004

No Improvement of Survival with Reduced versus High Intensity Conditioning for Allogeneic Stem Cell Transplants in Ewing Tumor Patients

U Thiel, A Wawer, P Wolf, et al. Annals of Oncology, 22(7):1614-1621, 2011. doi: 10.1093/annonc/mdq703